MDMA-Assisted CBT for OCD (MDMA-CBT4OCD Study)
The study assesses the safety and preliminary effectiveness of MDMA-assisted cognitive behavioral therapy in participants diagnosed with obsessive-compulsive disorder (OCD).
Stanford is currently not accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: 3,4-Methyl enedioxy methamphetamine
- drug: Methamphetamine
- behavioral: Cognitive Behavioral Therapy (CBT)
Eligibility
Inclusion Criteria:
1. At least 18 years old
2. Fluent in speaking and reading the predominantly used or recognized language of the
study site
3. Able to swallow pills
4. Meet the criteria for OCD diagnosis
5. YBOCS total score of at least 16
6. Not on psychotropic medications 1 month prior to study enrollment
7. Able to tolerate a treatment-free period
8. Able to tolerate study procedures
9. Failed at least 1 prior trial of standard first-line OCD treatment
10. Agree to the following lifestyle modifications: comply with requirements for fasting
and refraining from certain medications prior to the Experimental Session, not enroll
in any other interventional clinical trials during the duration of the study, and
commit to medication dosing, therapy, and study procedures.
Exclusion Criteria:
1. Pregnant or nursing, or able to become pregnant and are not practicing an effective
means of birth control
2. Weigh less than 48 kilograms (kgs)
3. Any current problem which, in the opinion of the investigator or study physician,
might interfere with participation
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Not Recruiting
Our research team includes physicians, residents, medical students, research assistants, and volunteers. Our research topics include medical imaging, device validation, mobile application development, and pharmaceutical trials.
Some of the Neuro-Opthalmic concerns we investigate include Multiple Sclerosis, Optic Neuritis, IIH, and ICP.